GSK U.S. Clinical Trial Registry Will Publicize Studies For Marketed Products
This article was originally published in The Pink Sheet Daily
Executive Summary
The registry appears to build upon an initiative launched by Glaxo Wellcome in 1998; that registry was only available to health care providers. The announcement closely follows the New York AG's lawsuit on Paxil study data, but GSK says the program has been under consideration for several months.
You may also be interested in...
GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
Merck Support For ClinicalTrials.Gov Expansion Does Not Mean Company Will Add Listings
Merck says it prefers to continue to fly below the radar screen with respect to ClinicalTrials.gov unless the law is changed. Merck's response to AMA's clinical trials registry proposal receives national media attention, but the company is an unlikely champion for government-sponsored public trial databases.